arrow
S

Sergio Bracarda

azienda ospedaliera s. maria
H指数:60
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

奥拉帕利在全球真实世界中对具有同源重组修复改变的转移性去势抵抗性前列腺癌患者的疗效

2026-08-310
OAAI
Evaluating the Gaps in Nutritional Care for Cancer Patients: Insights from the CIPOMO (Collegio Italiano Primari Oncologi Medici Ospedalieri) National Survey

评估癌症患者营养护理中的差距:来自CIPOMO(意大利医院内科肿瘤科主任协会)全国调查的见解

2026-08-120
OA
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings

AIMN、AIOM、AIRO、SIU、SIUrO和Meet-URO联合调查关于PSMA PET成像在意大利前列腺癌中的应用:PSA持续存在、生化复发、激素敏感性和去势抵抗性转移性设置

2026-08-012
OA
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting

AIMN、AIOM、AIRO、SIU、SIUrO 和 Meet-URO 关于意大利前列腺癌中PSMA PET成像使用的联合调查:技术方面和初始分期设置

2025-12-010
OAAI
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study

同源重组修复基因检测变量及前列腺癌患者的诊断路径:一项多中心队列研究

2025-12-010
PRE
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)

与毒性相关的免疫治疗停药及结局:接受基于免疫联合治疗方案的晚期肾细胞癌患者(ARON-1研究)

2025-11-040
PRE
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

ctDNA指导下的辅助阿特珠单抗治疗在肌肉浸润性膀胱癌中的应用

2025-10-0110
PRE
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

基因组匹配疗法在晚期实体瘤中的应用:随机II期ROME试验

2025-09-290
OAAI
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma

基于纳武利尤单抗的免疫疗法在真实世界老年转移性肾细胞癌患者中的疗效及通过Meet-URO评分进行的预后分层

2025-08-120
PRE
Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

G8老年综合评估筛查和Meet-URO评分在转移性肾细胞癌患者接受一线伊匹木单抗-纳武利尤单抗联合免疫治疗中的预后价值

2025-02-240
OA
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial

进展性前列腺癌患者开始使用多西他赛联合或不联合恩扎卢替尼时的液体活检:PRESIDE 3b期试验的生物标志物研究

2025-02-011
OAAI
Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies

将BRCA检测纳入常规前列腺癌护理: SIUrO和其他意大利科学学会的多学科方法

2025-01-230
OAAI
Subcutaneous versus intravenous nivolumab for renal cell carcinoma

皮下注射与静脉注射纳武利尤单抗治疗肾细胞癌

2025-01-010
OAAI
BRCA testing in metastatic castration-resistant prostate cancer: successes and troubles in a real world setting. An Italian Multicentric study
2024-10-010
OA
Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T

皮下注射纳武利尤单抗(NIVO SC)与静脉注射纳武利尤单抗(NIVO IV)在既往接受过治疗的晚期或转移性透明细胞肾细胞癌(ccRCC)患者(pts)中的疗效和安全性:CheckMate 67T研究的更新结果

2024-09-010
PRE